The control of DNMTs in SNCA locus is also confirmed by one recent study in which authors by using CRISPR-deactivated Cas9 (dCas9) fused with the catalytic domain of DNA-methyltransferase 3A (DNMT3A) claimed to reduce the expression levels of SNCA in human-induced pluripotent stem cell (hiPSC)–derived dopaminergic neurons from a PD patient with SNCA triplication44. This evidence concerns the gene DNMT3A and Parkinson disease.